4DX.AX - 4DMedical Limited

ASX - ASX Delayed price. Currency in AUD

4DMedical Limited

Melbourne Connect
Level 7 700 Swanston Street
Carlton, VIC 3053
61 3 9545 5940

IndustryMedical Devices
Full-time employees133

Key executives

NameTitlePayExercisedYear born
Dr. Andreas Fouras M.A.I.C.D., Ph.D.Founder, MD, CTO & CEO686.48kN/AN/A
Mr. John Andrew Livingston BAppSci, GradCertBus, GradDipHScExec. Director439.94kN/AN/A
Mr. Simon GloverChief Financial OfficerN/AN/AN/A
Mr. Craige Pendleton-Browne B.Sc., M.B.A.Chief Information OfficerN/AN/AN/A
Ms. Naomi LawrieCompany Sec. & Gen. CounselN/AN/AN/A
Mr. Clint RodgersVP of Marketing & CommunicationsN/AN/AN/A
Ms. Rachael TenkatenChief of StaffN/AN/AN/A
Mr. Paul Cooke B.A.Sr. VP of Strategy & Bus. Devel.N/AN/AN/A
Dr. Aidan Jamison B.E., Ph.D.Sr. VP of EngineeringN/AN/AN/A
Dr. Michael Curtis Ph.D.Chief Software ArchitectN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.

Corporate governance

4DMedical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.